Market Overview:
The global narcolepsy treatment market is expected to grow at a CAGR of 7.5% from 2018 to 2030. The growth in the market can be attributed to the increasing prevalence of narcolepsy, rising awareness about the condition, and technological advancements in the field of sleep medicine. The global narcolepsy treatment market is segmented on the basis of type, application, and region. On the basis of type, sodium oxybate accounts for a major share of the market owing to its high efficacy in treating cataplexy and other symptoms associated with narcolepsy. Central nervous system stimulants are also expected to witness significant growth during the forecast period due to their ability to improve wakefulness and reduce daytime sleepiness in people with narcolepsy. Antidepressants are another key segment of this market due to their ability to treat various symptoms associated with narcolepsy such as fatigue and depression.
Product Definition:
Narcolepsy Treatment is the use of medication or other therapies to treat narcolepsy. The importance of Narcolepsy Treatment is that it can help people with narcolepsy to stay awake during the day and reduce the symptoms of the disorder.
Sodium Oxybate:
Sodium oxybate is a sodium salt of hydroxypropyl-oxygen phosphate. It has been approved by the U.S. FDA for the treatment of narcolepsy and cataplexy in patients 18 years and older, but it is most effective when used in combination with other drugs that are used to treat these conditions (otherwise known as off-label).
The drug was first approved by the U.
Antidepressants:
Antidepressants are used to treat depression and other mental disorders. They help boost the levels of serotonin, a chemical in the brain, which helps improve the patient's mood. The most commonly prescribed antidepressants are selective serotonin reuptake inhibitors (SSRIs). SSRIs include Fluoxetine (Prozac), Paroxetine (Paxil), and Sertindol.
Application Insights:
Based on application, the global market is segmented into primary narcolepsy with cataplexy, primary narcolepsy without cataplexy, narcolepsy due to medical conditions and unspecified. Primary Narcolepsy with Cataplexy (PNCC) held the largest share in 2017 owing to increasing incidences of PNCC. According to a study published in The Journal of Clinical Sleep Medicine, PNCC accounted for around 24% of all cases ofNarCOLEPSY worldwide.
The use of sodium oxybate as a treatment for PNCC is gaining popularity due to its safety profile and effectiveness against depression along with other symptoms such as sleepiness and daytime fatigue which are commonly associated with this condition. However, there are no significant differences observed between sodium oxybate treated patients and controls while treating depression or any other disease states using similar drugs under clinical trials settings which may hinder market growth over the forecast period.
Regional Analysis:
North America dominated the global narcolepsy treatment market in 2017. The presence of key players, availability of better infrastructure and high awareness levels are some factors responsible for its large share. In addition, increasing cases of sleep-related disorders due to shift work are expected to drive the demand for treatments in this region. According to a study published by National Sleep Foundation in 2016, more than 60% of adults suffer from insomnia symptoms during weekdays as compared to only 40% suffering on weekends; these statistics highlight the importance of treating both types simultaneously rather than separately thus driving growth over this region.
Asia Pacific is expected to grow at a lucrative rate over the forecast period owing to rising disposable income and growing prevalence rates associated with various medical conditions that result in excessive tiredness such as cardiovascular diseases, diabetes & obesity which further leads into lack or sleep thus resulting into cataplexy attacks which drives growth over this region Narcolepsy Due To Medical Conditions).
Growth Factors:
- Increasing prevalence of narcolepsy
- Growing awareness about the symptoms and treatment of narcolepsy
- Rising demand for effective and safe treatments for narcolepsy
- Availability of government funding for research on new therapies for narcolepsy
- Technological advancements in the diagnosis and treatment of narcolepsy
Scope Of The Report
Report Attributes
Report Details
Report Title
Narcolepsy Treatment Market Research Report
By Type
Sodium Oxybate, Antidepressants, Central Nervous System Stimulants, Others
By Application
Primary Narcolepsy with Cataplexy, Primary Narcolepsy without Cataplexy, Narcolepsy Due to Medical Conditions, Unspecified Narcolepsy
By Companies
Teva Pharmaceutical, Takeda, Jazz Pharmaceuticals, Arena Pharmaceuticals, Graymark Healthcare, Ligand Pharmaceuticals
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
129
Number of Tables & Figures
91
Customization Available
Yes, the report can be customized as per your need.
Global Narcolepsy Treatment Market Report Segments:
The global Narcolepsy Treatment market is segmented on the basis of:
Types
Sodium Oxybate, Antidepressants, Central Nervous System Stimulants, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Primary Narcolepsy with Cataplexy, Primary Narcolepsy without Cataplexy, Narcolepsy Due to Medical Conditions, Unspecified Narcolepsy
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Teva Pharmaceutical
- Takeda
- Jazz Pharmaceuticals
- Arena Pharmaceuticals
- Graymark Healthcare
- Ligand Pharmaceuticals
Highlights of The Narcolepsy Treatment Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Sodium Oxybate
- Antidepressants
- Central Nervous System Stimulants
- Others
- By Application:
- Primary Narcolepsy with Cataplexy
- Primary Narcolepsy without Cataplexy
- Narcolepsy Due to Medical Conditions
- Unspecified Narcolepsy
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Narcolepsy Treatment Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
There is no one-size-fits-all answer to this question, as the best narcolepsy treatment will vary depending on the individual's specific symptoms and needs. However, some common treatments for narcolepsy include medication therapy, sleep training techniques, and cognitive behavioral therapy.
Some of the major players in the narcolepsy treatment market are Teva Pharmaceutical, Takeda, Jazz Pharmaceuticals, Arena Pharmaceuticals, Graymark Healthcare, Ligand Pharmaceuticals.
The narcolepsy treatment market is expected to grow at a compound annual growth rate of 7.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Narcolepsy Treatment Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Narcolepsy Treatment Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Narcolepsy Treatment Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Narcolepsy Treatment Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Narcolepsy Treatment Market Size & Forecast, 2020-2028
4.5.1 Narcolepsy Treatment Market Size and Y-o-Y Growth
4.5.2 Narcolepsy Treatment Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Sodium Oxybate
5.2.2 Antidepressants
5.2.3 Central Nervous System Stimulants
5.2.4 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Primary Narcolepsy with Cataplexy
6.2.2 Primary Narcolepsy without Cataplexy
6.2.3 Narcolepsy Due to Medical Conditions
6.2.4 Unspecified Narcolepsy
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Narcolepsy Treatment Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Narcolepsy Treatment Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Sodium Oxybate
9.6.2 Antidepressants
9.6.3 Central Nervous System Stimulants
9.6.4 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Primary Narcolepsy with Cataplexy
9.10.2 Primary Narcolepsy without Cataplexy
9.10.3 Narcolepsy Due to Medical Conditions
9.10.4 Unspecified Narcolepsy
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Sodium Oxybate
10.6.2 Antidepressants
10.6.3 Central Nervous System Stimulants
10.6.4 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Primary Narcolepsy with Cataplexy
10.10.2 Primary Narcolepsy without Cataplexy
10.10.3 Narcolepsy Due to Medical Conditions
10.10.4 Unspecified Narcolepsy
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Sodium Oxybate
11.6.2 Antidepressants
11.6.3 Central Nervous System Stimulants
11.6.4 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Primary Narcolepsy with Cataplexy
11.10.2 Primary Narcolepsy without Cataplexy
11.10.3 Narcolepsy Due to Medical Conditions
11.10.4 Unspecified Narcolepsy
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Sodium Oxybate
12.6.2 Antidepressants
12.6.3 Central Nervous System Stimulants
12.6.4 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Primary Narcolepsy with Cataplexy
12.10.2 Primary Narcolepsy without Cataplexy
12.10.3 Narcolepsy Due to Medical Conditions
12.10.4 Unspecified Narcolepsy
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Sodium Oxybate
13.6.2 Antidepressants
13.6.3 Central Nervous System Stimulants
13.6.4 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Primary Narcolepsy with Cataplexy
13.10.2 Primary Narcolepsy without Cataplexy
13.10.3 Narcolepsy Due to Medical Conditions
13.10.4 Unspecified Narcolepsy
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Narcolepsy Treatment Market: Competitive Dashboard
14.2 Global Narcolepsy Treatment Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Teva Pharmaceutical
14.3.2 Takeda
14.3.3 Jazz Pharmaceuticals
14.3.4 Arena Pharmaceuticals
14.3.5 Graymark Healthcare
14.3.6 Ligand Pharmaceuticals
